The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Melanoma Skin Cancer Diagnostic Testing Market Research Report 2025
Synopsis
Melanoma skin cancer is the most dangerous type of skin cancer. Development of defective DNA due to exposure to the ultraviolet radiation from sunlight or tanning beds leads to develop melanoma skin cancer. This genetic defect triggers mutation in the cell structure resulting in rapid multiplication of cells forming a malignant tumor. These malignant tumors often originate at basal layer of epidermis which produces melanocyte type of pigment which makes most of melanoma skin cancer black or brown in color. As per skin cancer foundation, in 2018 around 178,560 cases of melanoma will be diagnosed in United States alone. Melanoma skin cancer is the least common type of skin cancer and it is curable if diagnosed early. Early melanoma skin cancer diagnostic testing plays major role future treatment regimen and possible cure for the patient.
The global Melanoma Skin Cancer Diagnostic Testing market was valued at US$ 715 million in 2023 and is anticipated to reach US$ 1210.4 million by 2030, witnessing a CAGR of 7.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Melanoma Skin Cancer Diagnostic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Melanoma Skin Cancer Diagnostic Testing.
Report Scope
The Melanoma Skin Cancer Diagnostic Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Melanoma Skin Cancer Diagnostic Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Melanoma Skin Cancer Diagnostic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Myriad Genetics
Abbott Laboratories
Foundation Medicine
Pathway Genomics Corporation
Cancer Genetics
Castle Biosciences
NeoGenomics
Dermtech
Sysmex Inostics
Segment by Type
Biopsy
Imaging
Others
Segment by Application
Hospitals
Dermatology Clinics
Diagnostic Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Melanoma Skin Cancer Diagnostic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Melanoma skin cancer is the most dangerous type of skin cancer. Development of defective DNA due to exposure to the ultraviolet radiation from sunlight or tanning beds leads to develop melanoma skin cancer. This genetic defect triggers mutation in the cell structure resulting in rapid multiplication of cells forming a malignant tumor. These malignant tumors often originate at basal layer of epidermis which produces melanocyte type of pigment which makes most of melanoma skin cancer black or brown in color. As per skin cancer foundation, in 2018 around 178,560 cases of melanoma will be diagnosed in United States alone. Melanoma skin cancer is the least common type of skin cancer and it is curable if diagnosed early. Early melanoma skin cancer diagnostic testing plays major role future treatment regimen and possible cure for the patient.
The global Melanoma Skin Cancer Diagnostic Testing market was valued at US$ 715 million in 2023 and is anticipated to reach US$ 1210.4 million by 2030, witnessing a CAGR of 7.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Melanoma Skin Cancer Diagnostic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Melanoma Skin Cancer Diagnostic Testing.
Report Scope
The Melanoma Skin Cancer Diagnostic Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Melanoma Skin Cancer Diagnostic Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Melanoma Skin Cancer Diagnostic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Myriad Genetics
Abbott Laboratories
Foundation Medicine
Pathway Genomics Corporation
Cancer Genetics
Castle Biosciences
NeoGenomics
Dermtech
Sysmex Inostics
Segment by Type
Biopsy
Imaging
Others
Segment by Application
Hospitals
Dermatology Clinics
Diagnostic Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Melanoma Skin Cancer Diagnostic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Biopsy
1.2.3 Imaging
1.2.4 Others
1.3 Market by Application
1.3.1 Global Melanoma Skin Cancer Diagnostic Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Dermatology Clinics
1.3.4 Diagnostic Laboratories
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Melanoma Skin Cancer Diagnostic Testing Market Perspective (2019-2030)
2.2 Melanoma Skin Cancer Diagnostic Testing Growth Trends by Region
2.2.1 Global Melanoma Skin Cancer Diagnostic Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Melanoma Skin Cancer Diagnostic Testing Historic Market Size by Region (2019-2024)
2.2.3 Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Region (2025-2030)
2.3 Melanoma Skin Cancer Diagnostic Testing Market Dynamics
2.3.1 Melanoma Skin Cancer Diagnostic Testing Industry Trends
2.3.2 Melanoma Skin Cancer Diagnostic Testing Market Drivers
2.3.3 Melanoma Skin Cancer Diagnostic Testing Market Challenges
2.3.4 Melanoma Skin Cancer Diagnostic Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Melanoma Skin Cancer Diagnostic Testing Players by Revenue
3.1.1 Global Top Melanoma Skin Cancer Diagnostic Testing Players by Revenue (2019-2024)
3.1.2 Global Melanoma Skin Cancer Diagnostic Testing Revenue Market Share by Players (2019-2024)
3.2 Global Melanoma Skin Cancer Diagnostic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Melanoma Skin Cancer Diagnostic Testing Revenue
3.4 Global Melanoma Skin Cancer Diagnostic Testing Market Concentration Ratio
3.4.1 Global Melanoma Skin Cancer Diagnostic Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Melanoma Skin Cancer Diagnostic Testing Revenue in 2023
3.5 Melanoma Skin Cancer Diagnostic Testing Key Players Head office and Area Served
3.6 Key Players Melanoma Skin Cancer Diagnostic Testing Product Solution and Service
3.7 Date of Enter into Melanoma Skin Cancer Diagnostic Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Melanoma Skin Cancer Diagnostic Testing Breakdown Data by Type
4.1 Global Melanoma Skin Cancer Diagnostic Testing Historic Market Size by Type (2019-2024)
4.2 Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Type (2025-2030)
5 Melanoma Skin Cancer Diagnostic Testing Breakdown Data by Application
5.1 Global Melanoma Skin Cancer Diagnostic Testing Historic Market Size by Application (2019-2024)
5.2 Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Melanoma Skin Cancer Diagnostic Testing Market Size (2019-2030)
6.2 North America Melanoma Skin Cancer Diagnostic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2019-2024)
6.4 North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Melanoma Skin Cancer Diagnostic Testing Market Size (2019-2030)
7.2 Europe Melanoma Skin Cancer Diagnostic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2019-2024)
7.4 Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size (2019-2030)
8.2 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size (2019-2030)
9.2 Latin America Melanoma Skin Cancer Diagnostic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2019-2024)
9.4 Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size (2019-2030)
10.2 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Myriad Genetics
11.1.1 Myriad Genetics Company Detail
11.1.2 Myriad Genetics Business Overview
11.1.3 Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Introduction
11.1.4 Myriad Genetics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.1.5 Myriad Genetics Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Detail
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Introduction
11.2.4 Abbott Laboratories Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.2.5 Abbott Laboratories Recent Development
11.3 Foundation Medicine
11.3.1 Foundation Medicine Company Detail
11.3.2 Foundation Medicine Business Overview
11.3.3 Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Introduction
11.3.4 Foundation Medicine Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.3.5 Foundation Medicine Recent Development
11.4 Pathway Genomics Corporation
11.4.1 Pathway Genomics Corporation Company Detail
11.4.2 Pathway Genomics Corporation Business Overview
11.4.3 Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Introduction
11.4.4 Pathway Genomics Corporation Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.4.5 Pathway Genomics Corporation Recent Development
11.5 Cancer Genetics
11.5.1 Cancer Genetics Company Detail
11.5.2 Cancer Genetics Business Overview
11.5.3 Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Introduction
11.5.4 Cancer Genetics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.5.5 Cancer Genetics Recent Development
11.6 Castle Biosciences
11.6.1 Castle Biosciences Company Detail
11.6.2 Castle Biosciences Business Overview
11.6.3 Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Introduction
11.6.4 Castle Biosciences Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.6.5 Castle Biosciences Recent Development
11.7 NeoGenomics
11.7.1 NeoGenomics Company Detail
11.7.2 NeoGenomics Business Overview
11.7.3 NeoGenomics Melanoma Skin Cancer Diagnostic Testing Introduction
11.7.4 NeoGenomics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.7.5 NeoGenomics Recent Development
11.8 Dermtech
11.8.1 Dermtech Company Detail
11.8.2 Dermtech Business Overview
11.8.3 Dermtech Melanoma Skin Cancer Diagnostic Testing Introduction
11.8.4 Dermtech Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.8.5 Dermtech Recent Development
11.9 Sysmex Inostics
11.9.1 Sysmex Inostics Company Detail
11.9.2 Sysmex Inostics Business Overview
11.9.3 Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Introduction
11.9.4 Sysmex Inostics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
11.9.5 Sysmex Inostics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Biopsy
Table 3. Key Players of Imaging
Table 4. Key Players of Others
Table 5. Global Melanoma Skin Cancer Diagnostic Testing Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Melanoma Skin Cancer Diagnostic Testing Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Melanoma Skin Cancer Diagnostic Testing Market Share by Region (2019-2024)
Table 9. Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Melanoma Skin Cancer Diagnostic Testing Market Share by Region (2025-2030)
Table 11. Melanoma Skin Cancer Diagnostic Testing Market Trends
Table 12. Melanoma Skin Cancer Diagnostic Testing Market Drivers
Table 13. Melanoma Skin Cancer Diagnostic Testing Market Challenges
Table 14. Melanoma Skin Cancer Diagnostic Testing Market Restraints
Table 15. Global Melanoma Skin Cancer Diagnostic Testing Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Melanoma Skin Cancer Diagnostic Testing Market Share by Players (2019-2024)
Table 17. Global Top Melanoma Skin Cancer Diagnostic Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Melanoma Skin Cancer Diagnostic Testing as of 2023)
Table 18. Ranking of Global Top Melanoma Skin Cancer Diagnostic Testing Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Melanoma Skin Cancer Diagnostic Testing Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Melanoma Skin Cancer Diagnostic Testing Product Solution and Service
Table 22. Date of Enter into Melanoma Skin Cancer Diagnostic Testing Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Melanoma Skin Cancer Diagnostic Testing Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Melanoma Skin Cancer Diagnostic Testing Revenue Market Share by Type (2019-2024)
Table 26. Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Melanoma Skin Cancer Diagnostic Testing Revenue Market Share by Type (2025-2030)
Table 28. Global Melanoma Skin Cancer Diagnostic Testing Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Melanoma Skin Cancer Diagnostic Testing Revenue Market Share by Application (2019-2024)
Table 30. Global Melanoma Skin Cancer Diagnostic Testing Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Melanoma Skin Cancer Diagnostic Testing Revenue Market Share by Application (2025-2030)
Table 32. North America Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size by Country (2025-2030) & (US$ Million)
Table 47. Myriad Genetics Company Detail
Table 48. Myriad Genetics Business Overview
Table 49. Myriad Genetics Melanoma Skin Cancer Diagnostic Testing Product
Table 50. Myriad Genetics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 51. Myriad Genetics Recent Development
Table 52. Abbott Laboratories Company Detail
Table 53. Abbott Laboratories Business Overview
Table 54. Abbott Laboratories Melanoma Skin Cancer Diagnostic Testing Product
Table 55. Abbott Laboratories Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 56. Abbott Laboratories Recent Development
Table 57. Foundation Medicine Company Detail
Table 58. Foundation Medicine Business Overview
Table 59. Foundation Medicine Melanoma Skin Cancer Diagnostic Testing Product
Table 60. Foundation Medicine Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 61. Foundation Medicine Recent Development
Table 62. Pathway Genomics Corporation Company Detail
Table 63. Pathway Genomics Corporation Business Overview
Table 64. Pathway Genomics Corporation Melanoma Skin Cancer Diagnostic Testing Product
Table 65. Pathway Genomics Corporation Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 66. Pathway Genomics Corporation Recent Development
Table 67. Cancer Genetics Company Detail
Table 68. Cancer Genetics Business Overview
Table 69. Cancer Genetics Melanoma Skin Cancer Diagnostic Testing Product
Table 70. Cancer Genetics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 71. Cancer Genetics Recent Development
Table 72. Castle Biosciences Company Detail
Table 73. Castle Biosciences Business Overview
Table 74. Castle Biosciences Melanoma Skin Cancer Diagnostic Testing Product
Table 75. Castle Biosciences Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 76. Castle Biosciences Recent Development
Table 77. NeoGenomics Company Detail
Table 78. NeoGenomics Business Overview
Table 79. NeoGenomics Melanoma Skin Cancer Diagnostic Testing Product
Table 80. NeoGenomics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 81. NeoGenomics Recent Development
Table 82. Dermtech Company Detail
Table 83. Dermtech Business Overview
Table 84. Dermtech Melanoma Skin Cancer Diagnostic Testing Product
Table 85. Dermtech Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 86. Dermtech Recent Development
Table 87. Sysmex Inostics Company Detail
Table 88. Sysmex Inostics Business Overview
Table 89. Sysmex Inostics Melanoma Skin Cancer Diagnostic Testing Product
Table 90. Sysmex Inostics Revenue in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024) & (US$ Million)
Table 91. Sysmex Inostics Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Melanoma Skin Cancer Diagnostic Testing Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Melanoma Skin Cancer Diagnostic Testing Market Share by Type: 2023 VS 2030
Figure 3. Biopsy Features
Figure 4. Imaging Features
Figure 5. Others Features
Figure 6. Global Melanoma Skin Cancer Diagnostic Testing Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Melanoma Skin Cancer Diagnostic Testing Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Dermatology Clinics Case Studies
Figure 10. Diagnostic Laboratories Case Studies
Figure 11. Others Case Studies
Figure 12. Melanoma Skin Cancer Diagnostic Testing Report Years Considered
Figure 13. Global Melanoma Skin Cancer Diagnostic Testing Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Melanoma Skin Cancer Diagnostic Testing Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Melanoma Skin Cancer Diagnostic Testing Market Share by Region: 2023 VS 2030
Figure 16. Global Melanoma Skin Cancer Diagnostic Testing Market Share by Players in 2023
Figure 17. Global Top Melanoma Skin Cancer Diagnostic Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Melanoma Skin Cancer Diagnostic Testing as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Melanoma Skin Cancer Diagnostic Testing Revenue in 2023
Figure 19. North America Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Melanoma Skin Cancer Diagnostic Testing Market Share by Country (2019-2030)
Figure 21. United States Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Melanoma Skin Cancer Diagnostic Testing Market Share by Country (2019-2030)
Figure 25. Germany Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Melanoma Skin Cancer Diagnostic Testing Market Share by Region (2019-2030)
Figure 33. China Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Melanoma Skin Cancer Diagnostic Testing Market Share by Country (2019-2030)
Figure 41. Mexico Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Melanoma Skin Cancer Diagnostic Testing Market Share by Country (2019-2030)
Figure 45. Turkey Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Melanoma Skin Cancer Diagnostic Testing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Myriad Genetics Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 48. Abbott Laboratories Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 49. Foundation Medicine Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 50. Pathway Genomics Corporation Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 51. Cancer Genetics Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 52. Castle Biosciences Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 53. NeoGenomics Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 54. Dermtech Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 55. Sysmex Inostics Revenue Growth Rate in Melanoma Skin Cancer Diagnostic Testing Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
